Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren/HCTZ vs HCTZ in Hypertension Non-Responders
NCT00387517Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Mean sitting diastolic blood pressure lowering effect at 8 weeks. Started Oct 2006; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00387517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387517.